Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingshu-Yiqi-Tang is an Astragalus-based traditional Chinese medicine (TCM) herbal formula being developed by Chang Gung Memorial Hospital in Taiwan. It is currently being evaluated as an adjunct therapy for patients with advanced non-small cell lung cancer (NSCLC) who are receiving standard first-line doublet chemotherapy (such as cisplatin plus docetaxel or pemetrexed) and second-line targeted therapy (erlotinib). The formula is designed to modulate the immune system and reverse the immunosuppressive tumor microenvironment. Its primary mechanism involves targeting myeloid-derived suppressor cells (MDSCs) and regulatory T cells to prevent cytotoxic T cell apoptosis and restore anti-tumor immune functions, including natural killer (NK) cell activity and Th1 cell responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingshu-Yiqi-Tang.